Hydra Biosciences Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$22.6M
- Investors
-
1
Hydra Biosciences General Information
Description
Developer of molecular regeneration medicines intended to treat pain, inflammation, anxiety, and other diseases. The company's medicines focuses in the field of Transient Receptor Potential (TRP) ion channels, enabling doctors to address significant unmet medical needs easily.
Contact Information
Website
www.hydrabiosciences.comCorporate Office
- 45 Moulton Street
- Cambridge, MA 02138
- United States
Corporate Office
- 45 Moulton Street
- Cambridge, MA 02138
- United States
Hydra Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 01-Dec-2018 | $22.6M | Completed | Generating Revenue | ||
| 8. Later Stage VC (Series E) | 31-Mar-2015 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series D) | 16-Jan-2009 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 13-Mar-2008 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series B) | 12-Jan-2004 | Completed | Startup | |||
| 4. Accelerator/Incubator | 01-Jan-2003 | Completed | Startup | |||
| 3. Early Stage VC | 09-Oct-2002 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 25-Jul-2002 | $9.3M | $9.3M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2001 | Completed | Startup |
Hydra Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | ||||||||
| Series A1 | 1,065,004 | $0.001000 | 8% | $10 | $10 | 1x | $10 | |
| Series A | 1,065,004 | $0.001000 | 8% | $10 | $10 | 1x | $5.55 | 1.86% |
Hydra Biosciences Comparisons
Industry
Financing
Details
Hydra Biosciences Competitors (83)
One of Hydra Biosciences’s 83 competitors is Baliopharm, a Venture Capital-Backed company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| MicroCures | Venture Capital-Backed | Santa Cruz, CA | ||||
| Pharmacyclics | Venture Capital-Backed | San Francisco, CA |
Hydra Biosciences Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abbott | Corporation | Minority | ||
| Abbott Ventures | Corporate Venture Capital | Minority | ||
| Abingworth | Venture Capital | Minority | ||
| Acceleration International | Growth/Expansion | Minority | ||
| Advanced Technology Ventures | Venture Capital | Minority |
Hydra Biosciences FAQs
-
When was Hydra Biosciences founded?
Hydra Biosciences was founded in 2001.
-
Where is Hydra Biosciences headquartered?
Hydra Biosciences is headquartered in Cambridge, MA.
-
What industry is Hydra Biosciences in?
Hydra Biosciences’s primary industry is Drug Discovery.
-
Is Hydra Biosciences a private or public company?
Hydra Biosciences is a Private company.
-
What is the current valuation of Hydra Biosciences?
The current valuation of Hydra Biosciences is .
-
What is Hydra Biosciences’s current revenue?
The current revenue for Hydra Biosciences is .
-
How much funding has Hydra Biosciences raised over time?
Hydra Biosciences has raised $95.7M.
-
Who are Hydra Biosciences’s investors?
Abbott, Abbott Ventures, Abingworth, Acceleration International, and Advanced Technology Ventures are 5 of 14 investors who have invested in Hydra Biosciences.
-
Who are Hydra Biosciences’s competitors?
Baliopharm, Neurona Therapeutics, Orchard Therapeutics, MicroCures, and Pharmacyclics are some of the 83 competitors of Hydra Biosciences.
-
When was Hydra Biosciences acquired?
Hydra Biosciences was acquired on 01-Dec-2018.
-
Who acquired Hydra Biosciences?
Hydra Biosciences was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process